73
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Wnt signaling arrests effector T cell differentiation and generates CD8 + memory stem cells

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Self-renewing cell populations such as hematopoietic stem cells and memory B and T lymphocytes might be regulated by shared signaling pathways 1. Wnt/β-catenin is an evolutionarily conserved pathway that promotes hematopoietic stem cell self-renewal and multipotency by limiting stem cell proliferation and differentiation 2, 3, but its role in the generation and maintenance of memory T cells is unknown. We found that the induction of Wnt/β-catenin signaling using inhibitors of glycogen-sythase-kinase-3β or the Wnt protein family member, Wnt3a, arrested CD8 + T cell development into effector cells. By blocking T-cell differentiation, Wnt signaling enabled the generation of CD44 low, CD62L high, Sca-1 high, CD122 high, Bcl-2 high self-renewing, multipotent CD8 + memory stem cells with proliferative and anti-tumor capacities exceeding those of central and effector memory T cell subsets. These findings reveal a key role for Wnt signaling in the maintenance of stemness in mature memory CD8 + T cells and have important implications for the design of novel vaccination strategies and adoptive immunotherapies.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Lineage relationship and protective immunity of memory CD8 T cell subsets.

          Memory CD8 T cells can be divided into two subsets, central (T(CM)) and effector (T(EM)), but their lineage relationships and their ability to persist and confer protective immunity are not well understood. Our results show that T(CM) have a greater capacity than T(EM) to persist in vivo and are more efficient in mediating protective immunity because of their increased proliferative potential. We also demonstrate that, following antigen clearance, T(EM) convert to T(CM) and that the duration of this differentiation is programmed within the first week after immunization. We propose that T(CM) and T(EM) do not necessarily represent distinct subsets, but are part of a continuum in a linear naive --> effector --> T(EM) --> T(CM) differentiation pathway.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Asymmetric T lymphocyte division in the initiation of adaptive immune responses.

            A hallmark of mammalian immunity is the heterogeneity of cell fate that exists among pathogen-experienced lymphocytes. We show that a dividing T lymphocyte initially responding to a microbe exhibits unequal partitioning of proteins that mediate signaling, cell fate specification, and asymmetric cell division. Asymmetric segregation of determinants appears to be coordinated by prolonged interaction between the T cell and its antigen-presenting cell before division. Additionally, the first two daughter T cells displayed phenotypic and functional indicators of being differentially fated toward effector and memory lineages. These results suggest a mechanism by which a single lymphocyte can apportion diverse cell fates necessary for adaptive immunity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

              Many tumor-associated antigens are derived from nonmutated “self” proteins. T cells infiltrating tumor deposits recognize self-antigens presented by tumor cells and can be expanded in vivo with vaccination. These T cells exist in a functionally tolerant state, as they rarely result in tumor eradication. We found that tumor growth and lethality were unchanged in mice even after adoptive transfer of large numbers of T cells specific for an MHC class I–restricted epitope of the self/tumor antigen gp100. We sought to develop new strategies that would reverse the functionally tolerant state of self/tumor antigen-reactive T cells and enable the destruction of large (with products of perpendicular diameters of >50 mm2), subcutaneous, unmanipulated, poorly immunogenic B16 tumors that were established for up to 14 d before the start of treatment. We have defined three elements that are all strictly necessary to induce tumor regression in this model: (a) adoptive transfer of tumor-specific T cells; (b) T cell stimulation through antigen-specific vaccination with an altered peptide ligand, rather than the native self-peptide; and (c) coadministration of a T cell growth and activation factor. Cells, vaccination, or cyto-kine given alone or any two in combination were insufficient to induce tumor destruction. Autoimmune vitiligo was observed in mice cured of their disease. These findings illustrate that adoptive transfer of T cells and IL-2 can augment the function of a cancer vaccine. Furthermore, these data represent the first demonstration of complete cures of large, established, poorly immunogenic, unmanipulated solid tumors using T cells specific for a true self/tumor antigen and form the basis for a new approach to the treatment of patients with cancer.
                Bookmark

                Author and article information

                Journal
                9502015
                8791
                Nat Med
                Nature medicine
                1078-8956
                1546-170X
                14 May 2009
                14 June 2009
                July 2009
                1 January 2010
                : 15
                : 7
                : 808-813
                Affiliations
                [1 ] Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
                Author notes
                Address correspondence to Luca Gattinoni or Nicholas P. Restifo, National Cancer Institute, National Institutes of Health, Clinical Research Center, Room 3-5762, 10 Center Drive, Bethesda, MD 20892-1502. E-mail: (LG): gattinol@ 123456mail.nih.gov , (NPR): restifo@ 123456nih.gov
                [*]

                These authors contributed equally to the present work.

                Article
                nihpa115647
                10.1038/nm.1982
                2707501
                19525962
                bfde8585-5a5b-4080-b466-7cc5f176ad4b
                History
                Funding
                Funded by: Division of Basic Sciences : NCI
                Award ID: Z01 BC010763-02 ||BC
                Categories
                Article

                Medicine
                Medicine

                Comments

                Comment on this article